Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Neuroblastoma and GD2-Positive Tumors With Activated T Cells Armed With OKT3 X Humanized 3F8 Bispecific Antibodies (GD2Bi): A Phase I/II Study

NCT02173093 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

NCT NCT02173093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02173093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Neuroblastoma and GD2-Positive Tumors With Activated T Cells Armed With OKT3 X Humanized 3F8 Bispecific Antibodies (GD2Bi): A Phase I/II Study
Lead sponsor
University of Virginia
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 30, 2014
Completion date
December 31, 2019
Enrollment
40 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

disseminated neuroblastoma, recurrent neuroblastoma